Versant-backed Seawolf raises $100 million seed and Series A, signs Sanofi deal

· VC Investment

TLDR

  • Seawolf, a San Diego DNA-medicine start-up, emerged from stealth with $100 million across seed and Series A rounds.12
  • It also announced a Sanofi collaboration worth up to $1.2 billion in milestones plus royalties, according to the company.13
  • Its lead programme has been tested only in animals, and the Sanofi upfront payment was not disclosed.4

Seawolf Therapeutics, a San Diego biotechnology company, said on 16 November 2026 that it had emerged from stealth "having raised $100 million" for its DNA delivery platform.1 Versant Ventures, the "founding investor", led the seed round, followed by a Series A with Versant, MPM BioImpact and Novartis Venture Fund, and "participation from" Eli Lilly, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments and Pathway to Cures, the philanthropic venture arm of the National Bleeding Disorders Foundation.1 The release names no Series A lead and does not split the $100 million between the two rounds; Fierce Biotech describes the total as a combination of the seed and the Series A.13 BioPharma Dive reports the same investors.2 No valuation was given in the sources opened.

Seawolf also announced a "multi-target research collaboration and exclusive license agreement" with Sanofi, to develop undisclosed therapies for bleeding disorders and further unnamed indications.1 Seawolf could receive "up to $1.2 billion in research, development & commercial milestones", plus tiered royalties on sales of any resulting products.1 "Up to" is a ceiling that depends on milestones being met, not cash received. Chief executive Elizabeth Alcamo told Reuters the agreement includes an upfront payment but declined to give the amount.4 The terms come from Seawolf's release; we found no separate Sanofi announcement, so the deal is company-reported.

The platform, TRIDENT, packages "immune quiet DNA" encoding a therapeutic gene, together with an "auxiliary factor" that helps it reach the cell nucleus, inside a lipid nanoparticle (LNP).1 Seawolf says this matches RNA-based LNP medicines on potency and safety while overcoming their short-lived expression, and, unlike virus-based DNA platforms, can be redosed.1 BioPharma Dive notes the safety and durability claims rest on company-reported primate tests.2 Alcamo told Fierce the goal is for patients who need regular infusions of antibodies or recombinant proteins to dose as rarely as every six months or yearly.3

The lead programme targets metabolic disease. Reuters reported that it has been tested only in animals, aims to build muscle and reduce fat, and could be used for obesity, muscle loss and osteoporosis.4 Alcamo said Seawolf expects to pick a drug candidate by late 2027 and file to begin human trials by the end of 2028, but "we'll probably need to raise some additional capital" to get there.4 BioSpace noted the company shared no other specifics about the lead asset, and Endpoints News framed the launch around the same three indications.56

Fierce calls Alcamo the company's founder and says it started in 2021.3 BioSpace describes her as a former Versant entrepreneur in residence with earlier senior roles at CODA Biotherapeutics and 4D Molecular Therapeutics.5 Versant's Tom Woiwode chairs the board, and the sources opened name no other founders.1 Novartis Venture Fund lists Seawolf as developing "redosable, durable non-viral DNA-based medicines".7

BioPharma Dive adds that metabolic disease is an area where venture money has cooled: about $740 million from 26 prolific biotech venture firms so far this year, against nearly $1.3 billion in 2025 and $1.6 billion in 2024, by its own tally.2

Why it matters: a start-up with animal-only data raised $100 million from a venture and pharma syndicate in a cooling metabolic-disease market, but its headline Sanofi figure is a company-reported milestone ceiling and the upfront payment is undisclosed.124

Sources

  1. Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics (Business Wire (Seawolf Therapeutics))
  2. Big-name investors pour $100M into DNA therapeutics developer Seawolf (BioPharma Dive)
  3. Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact (Fierce Biotech)
  4. DNA drug developer Seawolf launches with $100 million funding, Sanofi deal (Reuters (via Global Banking & Finance Review))
  5. Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicines (BioSpace)
  6. Seawolf launches with $100M to make non-viral gene therapies for obesity, muscle loss and osteoporosis (Endpoints News)
  7. Seawolf Therapeutics (Novartis Venture Fund)